EuMentis Therapeutics
EuMentis Therapeutics is a clinical stage biopharmaceutical company dedicated to developing novel therapies for serious neuropsychiatric conditions. The company integrates clinically validated science with cutting-edge technology to create effective treatments for conditions like Tourette syndrome and autism spectrum disorder, focusing on restoring balance in neurotransmitter systems.
What We Do
EM-221
A novel PDE10A inhibitor designed to reduce dopamine signaling in patients with Tourette syndrome, aiming to alleviate motor and vocal tics without the side effects associated with current FDA-approved medications.
EM-113
A noncompetitive, low-trapping glutamate antagonist aimed at treating autism spectrum disorder by restoring glutamate equilibrium without causing serious side effects.
NMDA Antagonist for Traumatic Brain Injury
A treatment under development to address the excess glutamate released after traumatic brain injury, which can lead to further neuronal damage.
Psychological and Cognitive Health and Performance
Drugs
Services
Regenerative Medicine
Digital Health Technologies
Key People
Mark A. Tepper, PhD
President & CEO
Randall Marshall, MD
Chief Medical Officer
Joanne Emmett
Head of Clinical Operations
Xiaoming Zhang, PhD
Head of CMC
Dylan Wenke
VP of Finance and Operations
News & Updates
Randall Marshall, MD, will present at the Tourette Association of America’s TIC-CON24 Research Symposium in Dallas, Texas.
Randall Marshall, MD, will present a keynote address at the Autism Parenting Summit held virtually.
EuMentis Therapeutics Inc. received a $3 million award from the United States Department of Defense to advance its novel NMDA receptor antagonist for traumatic brain injury.